Schrödinger develops physics-based computational software for molecular discovery and design, serving pharmaceutical, biotechnology and materials science customers from offices in five countries.
Schrödinger develops physics-based computational software for molecular discovery and design, serving biopharmaceutical and industrial customers across the pharmaceuticals, biotechnology and materials science sectors. Founded in 1990, the company builds simulation tools that let researchers predict molecular properties with high accuracy, integrating physics-based methods with machine learning to support the identification of novel therapeutics and materials.
The company's platform is the product of more than 30 years of research and development investment. Its technical work spans physics-based computational simulation, machine learning, molecular modeling and molecular property prediction. The commercial proposition is straightforward: predictive accuracy applied early in a discovery programme, whether in drug discovery or materials design, reduces the cost of experimental iteration.
Schrödinger operates from offices in five countries - the USA, UK, Germany, India and Japan - reflecting a distributed research and engineering footprint. Scientists and engineers work together across these locations, with an emphasis on collaborative research, professional development and flexible working arrangements.
The company describes its mission as improving human health and quality of life. Roles at Schrödinger typically sit at the intersection of scientific research and software engineering, in domains including computational chemistry, molecular simulation and applied machine learning.
